secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2025-01-31T23:59:59+00:00
Accession:  0001551152-25-000011
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie Q4 GAAP loss $0.02 (emraclidine impairment), adj. EPS $2.16; FY rev $56.3B, 2025 adj. EPS guide $12.12-12.32
--------------------------------------------------------------------------------

- Q4 revenue $15.102B (+5.6% reported); full-year revenue $56.334B (+3.7% reported).
- Q4 GAAP diluted loss per share $0.02 (includes $3.5B impairment for emraclidine); adjusted diluted EPS $2.16.
- Global Skyrizi revenue $3.778B (+57.7%) in Q4; Rinvoq revenue $1.834B (+46.2%); Humira revenue -49.1% to $1.682B.
- 2025 adjusted EPS guidance $12.12-$12.32; raises 2027 Skyrizi+Rinvoq revenue outlook to >$31B.
- Full-year immunology revenue $26.682B (+2.1%); neuroscience $8.999B (+16.6%); aesthetics $5.176B (-2.2%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115225000011/0001551152-25-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115225000011/abbv-20250131.htm
  HTML page:      https://secwatch.observer/filing/0001551152-25-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer